RALLIS CHRIS A 4
4 · FENNEC PHARMACEUTICALS INC. · Filed Dec 2, 2024
Insider Transaction Report
Form 4
RALLIS CHRIS A
Director
Transactions
- Sale
Common Shares
2024-12-02$6.14/sh−6,409$39,351→ 52,214 total - Exercise/Conversion
Common Shares
2024-12-02$2.69/sh−10,000$26,900→ 184,698 totalExercise: $2.69From: 2014-12-31Exp: 2024-12-31→ Options (10,000 underlying) - Exercise/Conversion
Common Shares
2024-12-02$2.69/sh+10,000$26,900→ 58,623 total
Footnotes (3)
- [F1]Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on August 17, 2023.
- [F2]Shares sold to satisfy tax obligation on option exercise.
- [F3]Represents options exercised pursuant to a 10b5-1 plan adopted on August 17, 2023.